sirolimus + tacrolimus + mycophenolate mofetil

Sirolimus, tacrolimus, and mycophenolate mofetil represent a combination immunosuppressive regimen primarily utilized in organ transplantation, particularly for the prophylaxis of kidney transplant rejection. Each component acts through a distinct mechanism to suppress the immune system and prevent the body from attacking the transplanted organ. Sirolimus, also known as rapamycin, is a macrolide compound that functions as a mammalian target of rapamycin (mTOR) kinase inhibitor. It binds to the cytosolic protein FKBP12, and this complex then inhibits mTOR Complex 1 (mTORC1), thereby blocking cell-cycle progression at the G1 to S phase transition and inhibiting T-cell and B-cell proliferation and antibody production. Tacrolimus, a macrolide lactone also known as FK506, is a calcineurin inhibitor. It binds to FKBP12, and this complex then inhibits calcineurin, an enzyme crucial for T-cell activation. This action prevents the dephosphorylation of the nuclear factor of activated T cells (NF-AT), blocking its translocation to the nucleus and suppressing the transcription of interleukin-2 (IL-2) and other cytokines required for T-cell proliferation. Mycophenolate mofetil (MMF) is a prodrug that is metabolized to its active form, mycophenolic acid (MPA). MPA is a selective, non-competitive, and reversible inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH), an enzyme essential for the de novo synthesis of guanosine nucleotides. Lymphocytes are highly dependent on this pathway for proliferation, making them particularly susceptible to MPA's effects, which results in the inhibition of T-cell and B-cell proliferation and maturation, thereby suppressing cell-mediated immune responses and antibody formation. MMF also inhibits the glycosylation and expression of adhesion molecules and can induce apoptosis of activated T-lymphocytes. The combined action of these three agents provides synergistic immunosuppression, allowing for reduced doses of individual drugs and mitigating toxicity while maintaining adequate immune suppression to prevent organ rejection. This regimen is commonly used in kidney, heart, and liver transplant recipients.

Brand names

RapamunePrografCellCept

Other names

Sirolimus/Tacrolimus/MMF regimenSirolimus + Tacrolimus + Mycophenolate mofetil